RXi and EyeGate eye deal on non-invasive ocular RNAi delivery
RXi Pharmaceuticals and EyeGate Pharma will unite to develop non-invasive, needle-free ocular delivery of RNAi therapeutics using the EyeGate II system for the treatment of retinal disorders.